Menu
PacPremier
Magic Hour
Montecito
SoCal Gas
Loading...
You are here:  Home  >  'FDA'
Latest

FDA accuses Amgen of misleading advertising

By   /  Friday, July 16th, 2021  /  Banking & Finance, Biotech, Central Coast Health Watch, East Ventura County, Latest news, Top Stories, Tri-County Economy, Tri-County Public Companies  /  Comments Off on FDA accuses Amgen of misleading advertising

The U.S. Food and Drug Administration tagged Amgen with a letter July 7 that says the Thousand Oaks biotech firm made “misleading claims” in advertisements for its drug Neulasta, by suggesting it is more effective than biosimilar competitors. Neulasta is a prescription medication used to reduce infection risk from febrile neutropenia (a low level of Read More →

Read More →
Latest

FDA gives Amgen priority review for asthma treatment

By   /  Friday, July 9th, 2021  /  Banking & Finance, Biotech, Central Coast Health Watch, East Ventura County, Latest news, Top Stories, Tri-County Economy, Tri-County Public Companies  /  Comments Off on FDA gives Amgen priority review for asthma treatment

Thousand Oaks-based Amgen received a priority review for tezepelumab, a treatment for asthma, from the U.S. Food and Drug Administration, the biotech giant announced July 7. According to Amgen, tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of clients in phase 2 and 3 trials. Read More →

Read More →
Latest

Amgen gets FDA approval for potential billion-dollar drug

By   /  Friday, May 28th, 2021  /  Banking & Finance, Biotech, East Ventura County, Latest news, right, Top Stories, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen gets FDA approval for potential billion-dollar drug

Thousand Oaks-based Amgen won approval from the U.S. Food and Drug Administration on May 28 for its latest oral drug treatment, Lumakras, potentially adding another huge market for one of the largest biotech firms in the world. According to the Wall Street Journal, Amgen will charge $17,900 a month for the drug and analyst think Read More →

Read More →
Latest

Feds back away from fee for distilleries that made hand sanitizer

By   /  Friday, January 8th, 2021  /  Central Coast Health Watch, Latest news, middle, Small Business, Subscriber content, Top Stories  /  Comments Off on Feds back away from fee for distilleries that made hand sanitizer

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Atara Biotherapeutics raises $175 million

By   /  Friday, June 5th, 2020  /  Biotech, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Atara Biotherapeutics raises $175 million

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Sienna Biopharmaceuticals’ struggles doomed company

By   /  Friday, December 20th, 2019  /  Biotech, Central Coast Health Watch, East Ventura County, Latest news, Law, Tri-County Public Companies  /  Comments Off on Sienna Biopharmaceuticals’ struggles doomed company

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen seeks license for biosimilar version of oncology drug Rituxan

By   /  Thursday, December 19th, 2019  /  Biotech, Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on Amgen seeks license for biosimilar version of oncology drug Rituxan

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →